Histiocytosis
Nationally ranked by U.S. News & World Report
The Histiocytosis Program at Children’s Mercy provides a comprehensive setting for care of rare diseases. Our experienced team collaborates to treat conditions such as Langerhans Cell Histiocytosis, Hemophagocytic Lymphohistiocytosis, sinus histiocytosis with massive lymphadenopathy, and Erdheim-Chester disease.
Our program provides a team approach to care that features collaborations between multiple services when needed. Our team includes the expertise of a pediatric hematologist/oncologist, pediatric nurse practitioner, and a pediatric social worker. The Histiocytosis Program collaborates with pediatric orthopedic surgeons, pediatric endocrinologists, pediatric dermatologists, and pediatric pathologists.
Areas of research focus
Our team is working on a HLH-prospective study looking at cytokine levels in the Pediatric Intensive Care Unit, collaborating with Allergy/Immunology and Critical Care Medicine.
Each year, the Division of Pediatric Hematology, Oncology and Bone Marrow Transplantation at Children’s Mercy Kansas City provides comprehensive care to nearly 2,000 children with childhood cancers, sickle cell disease, hemophilia and other blood disorders, with survival rates frequently above national averages.
Our commitment to clinical research and innovation has helped us earn recognition as one of the top cancer programs for kids in the nation by U.S. News and World Report. Children’s Mercy also has received accreditation from the American College of Surgeons Commission on Cancer and the Foundation for Accreditation of Cellular Therapy.